en
Scientific article
English

Double-blind studies are not always optimum for evaluation of a novel therapy: the case of new anticoagulants

Published inJournal of thrombosis and haemostasis, vol. 6, no. 2, p. 227-229
Publication date2008
Keywords
  • Anticoagulants/standards/therapeutic use
  • Bias (Epidemiology)
  • Case Management
  • Clinical Trials, Phase III as Topic/methods/standards
  • Cost-Benefit Analysis
  • Double-Blind Method
  • Fibrinolytic Agents/standards/therapeutic use
  • Heparin/therapeutic use
  • Heparin, Low-Molecular-Weight/therapeutic use
  • Humans
  • Patient Selection
  • Professional Practice
  • Prothrombin Time/instrumentation
  • Quality of Life
  • Randomized Controlled Trials as Topic/methods/standards
  • Thrombophilia/drug therapy
  • Treatment Outcome
  • Vitamin K/antagonists & inhibitors
Citation (ISO format)
BULLER, Harry R. et al. Double-blind studies are not always optimum for evaluation of a novel therapy: the case of new anticoagulants. In: Journal of thrombosis and haemostasis, 2008, vol. 6, n° 2, p. 227–229. doi: 10.1111/j.1538-7836.2007.02848.x
Main files (1)
Article (Accepted version)
accessLevelRestricted
Identifiers
ISSN of the journal1538-7836
525views
0downloads

Technical informations

Creation06/02/2009 8:39:00 AM
First validation06/02/2009 8:39:00 AM
Update time03/14/2023 3:06:03 PM
Status update03/14/2023 3:06:03 PM
Last indexation01/15/2024 6:31:12 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack